Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 915-730-3 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Acute toxicity for OTNE:
- Oral (OECD TG 401): LD50 >5000 mg/kg bw
- Dermal (OECD TG 402): LD50 >5000 mg/kg bw
- Inhalation (route to route extrapolation from acute oral information): LD50 > 22360 mg/m3
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Quality of whole database:
- The acute oral toxicity result is of sufficient quality and adequate for this dossier.
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Quality of whole database:
- The derived acute inhalation toxicity result is of sufficient quality and sufficiently adequate for this dossier.
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 18 March 1980 - 1 April 1980
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study performed similar to the OECD TG 402 "Acute Dermal Toxicity", 1987, but was not performed under GLP. Report is well documented, and the design is considered scientifically accepted.
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- yes
- Remarks:
- 8 male and 8 female rat, one dose tested
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Breeding Labs (Wilmington, Mass., USA)
- Age at study initiation: no data
- Weight at study initiation: 180 to 280 grams
- Housing: singly in wire cages under standard laboratory conditions meeting the standards described in the 'Guide for the Care and Use of Laboratory Animals' (DHEW Publication No. (NIH) 78-23 Revised 1978).
- Diet: Purina Rodent Laboratory Chow 5001 ad libitum
- Water: ad libitum
- Acclimation period: 7 days
ENVIRONMENTAL CONDITIONS: no data
IN-LIFE DATES: no data - Type of coverage:
- open
- Vehicle:
- other: SDA39C (alcoholic solution)
- Details on dermal exposure:
- TEST SITE
- Area of exposure: area bounded by the nape of the neck, the mid dorsum between pectoral and pelvic girdles and the lateral aspects of the scapulae (the backs of the rats were clipped from the scapular region to the hips a day prior to treatment)
- % coverage: less than 30% of the body surface
REMOVAL OF TEST SUBSTANCE
- Washing (if done): wiping with a clean cloth
- Time after start of exposure: 24 hours
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 0.5 ml/100 g bw
- Concentration (if solution): 5000 mg/kg bw
- Constant volume or concentration used: yes, constant concentration - Duration of exposure:
- 24 hours
- Doses:
- 5000 mg/kg bw
- No. of animals per sex per dose:
- 8 males and 8 females
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: mortality and pharmacotoxic signs: at 1, 3, 5 and 24 hours following dosing and twice daily (once daily on weekends) for the remainder of the 14 day observation period. Weighing: Pre-dose and Day 14.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight, other: necropsy-tissues examined: lungs, heart, liver, spleen, kidney, adrenals, bladder, stomach, intestines. Other tissues examined grossly: the external carcass (fur, skin and orifices), peritoneal and pleural mucosa, internal mesentery. - Preliminary study:
- In a preliminary range finding assay in which two rats (one of each sex) were treated at 5000 mg/kg bw., there were no deaths during the 72 hour observation period.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 5 000 mg/kg bw
- Remarks on result:
- other: No mortality noted at this dose level.
- Mortality:
- No mortality was seen in the 8 males and 8 females dosed with the test article.
- Clinical signs:
- There were no clinical signs of toxicity in any animal dosed at 5000 mg/kg bw. All the animals appeared normal in health and behavior throughout the 14 day observation period.
- Body weight:
- The animals all gained weight in a normal pattern (10 g or more).
- Gross pathology:
- There were no signs indicative of toxicity in any of the rats necropsied at term. No visible lesions in the tissues examined.
- Interpretation of results:
- other: criteria are not met
- Remarks:
- according to EU CLP (1272/2008 and its amendments)
- Conclusions:
- This study found no effects that related to acute dermal toxicity in rats after administrating a single dose of 5000 mg/kg bw. The LD50 was in excess of 5000 mg/kg.
- Executive summary:
The dermal acute toxicity of the substance, a yellow liquid, was examined according to a similar to OECD TG 402, 1987, protocol. First a preliminary study was performed with x males and females. In the final study eight male and eight female albino rats (Sprague-Dawley CD strain) were used. The animals weighing between 180 and 280 grams, were clipped on the day prior to dosing and the test substance, prepared in the diluent supplied, was applied onto the skin at 5000 mg/kg bw. The volume of the solution administered was 0.5 ml/100 g bw.
In the preliminary study no mortality occurred in 72h. In the main study none of the test animals showed any clinical signs indicative of systemic toxicity. All of the animals remained healthy throughout the study and gained weight in a normal manner. At necropsy performed on the survivors at term, none of the animals had any signs indicative of systemic toxicity. The dermal LD50 was greater than 5000 mg/kg bw.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Quality of whole database:
- The acute dermal toxicity result is of sufficient quality and adequate for this dossier.
Additional information
Acute oral toxicity
The acute oral toxicity of the test substance was examined in a limit test. In a preliminary assay in which two rats were treated by gavage at 5000 mg/kg bw, there were no deaths during the 72 hour observation period. Ten male and ten female albino rats (TacN(SD)fBR) weighing between 180 and 280 grams were fasted overnight and were then dosed by gavage with 5000 mg/kg bw of the test article. None of the animals showed any pharmacological effect or clinical sign indicative of toxicity. All of the animals appeared normal in health and behaviour throughout the study. There were no deaths. At necropsy, none of the animals had any signs indicative of systemic toxicity. The LD50 was in excess of 5000 mg/kg under the conditions of the current study and the compound was therefore assessed as practically non-toxic. Based on EU criteria the substance does not have to be classified as acute toxic (oral).
Acute inhalation toxicity
The acute inhalation toxicity for the substance can be derived using data on the acute oral toxicity using the following methodology:CLP guidance (2017, 3.1.5.1.8. Example 8, page 264):using the extrapolation formula 1 mg/kg bw = 0.0052 mg/l/4h.
The LD50 of the substance for acute oral toxicity is > 5000 mg/kg bw. This 5000 mg/kg bw can be converted to > 26 mg/l = 26 gram/m3. Taking into account the inhalation absorption as 100% and oral absorption 86%, the acute inhalation toxicity would become =>22360 mg/kg bw.
The saturated vapour pressure of the substance is: 48.5 mg/m3 (MW*VapPres/ (8.3*293). This means that the acute inhalation LC50 > 22360 mg/m3 cannot be reached because it exceeds the saturated vapour pressure by more than a factor of 400 (461).
Acute dermal toxicity
The dermal acute toxicity of the test substance, a yellow liquid, was examined (similar to OECD test guideline 402, 1987). In a preliminary assay in which two rats of each sex were dosed by application of a prepared alcoholic solution of the test substance to the skin at 5000 mg/kg bw, there were no deaths during the 72 hour observation period. Eight male and eight female albino rats (Sprague-Dawley CD strain), weighing between 180 and 280 grams, were clipped on the day prior to dosing and the test substance, prepared in the diluent supplied, was applied onto the skin at 5000 mg/kg bw. The volume of the solution administered was 0.5 ml/100 g bw.
None of the test animals showed any clinical signs indicative of systemic toxicity. All of the animals remained healthy throughout the study and gained weight in a normal manner. At necropsy performed on the survivors at term, none of the animals had any signs indicative of systemic toxicity. The dermal LD50 was greater than 5000 mg/kg bw.
Justification for classification or non-classification
Based on the available information in the dossier, the substance OTNE does not need to be classified for acute toxicity via the oral, dermal, and inhalation route when considering the criteria outlined in the EU CLP (EC 1272/2008 and its amendments).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

Route: .live1